GOALS OF THE WORK: The goal of this study was to examine the association between exercise and quality of life (QOL) in multiple myeloma cancer survivors. PATIENTS AND METHODS: Using a retrospective design, 156 multiple myeloma cancer survivors were mailed a questionnaire that assessed self-reported exercise behavior over three periods (prediagnosis, active treatment, and off-treatment) and QOL. MAIN RESULTS: The response rate was 56% (88/ 156). Descriptive analyses indicated that 6.8% and 20.4% of survivors met national exercise guidelines during active and off-treatment periods, respectively. Exercise during active treatment and off-treatment were positively associated with overall QOL and all subdomains of QOL (all P<0.05) except physical wellbeing. CONCLUSIONS: A low percentage of multiple myeloma cancer survivors are exercising regularly either during active or off-treatment periods. Survivors who report more exercise during these periods also report higher QOL. These findings suggest that a randomized controlled trial is warranted.
GOALS OF THE WORK: The goal of this study was to examine the association between exercise and quality of life (QOL) in multiple myeloma cancer survivors. PATIENTS AND METHODS: Using a retrospective design, 156 multiple myeloma cancer survivors were mailed a questionnaire that assessed self-reported exercise behavior over three periods (prediagnosis, active treatment, and off-treatment) and QOL. MAIN RESULTS: The response rate was 56% (88/ 156). Descriptive analyses indicated that 6.8% and 20.4% of survivors met national exercise guidelines during active and off-treatment periods, respectively. Exercise during active treatment and off-treatment were positively associated with overall QOL and all subdomains of QOL (all P<0.05) except physical wellbeing. CONCLUSIONS: A low percentage of multiple myeloma cancer survivors are exercising regularly either during active or off-treatment periods. Survivors who report more exercise during these periods also report higher QOL. These findings suggest that a randomized controlled trial is warranted.
Authors: K S Courneya; C M Friedenreich; H A Quinney; A L A Fields; L W Jones; A S Fairey Journal: Eur J Cancer Care (Engl) Date: 2003-12 Impact factor: 2.520
Authors: Lee W Jones; Bebe Guill; Stephen T Keir; Karen Carter; Henry S Friedman; Darell D Bigner; David A Reardon Journal: Support Care Cancer Date: 2006-07-04 Impact factor: 3.603
Authors: Jae Youn Chung; Dong Hoon Lee; Ji-Hye Park; Mi Kyung Lee; Dong-Woo Kang; Jihee Min; Dong-Il Kim; Duck Hyoun Jeong; Nam Kyu Kim; Jeffrey A Meyerhardt; Lee W Jones; Justin Y Jeon Journal: Support Care Cancer Date: 2013-01-06 Impact factor: 3.603
Authors: Lee W Jones; Marina Mourtzakis; Katherine B Peters; Allan H Friedman; Miranda J West; Stephanie K Mabe; William E Kraus; Henry S Friedman; David A Reardon Journal: Oncologist Date: 2010-05-18
Authors: Maria Gabriella Giganti; Ilaria Tresoldi; Roberto Sorge; Giovanni Melchiorri; Tamara Triossi; Laura Masuelli; Paolo Lido; Loredana Albonici; Calogero Foti; Andrea Modesti; Roberto Bei Journal: Oncol Lett Date: 2016-07-20 Impact factor: 2.967
Authors: Kristina H Karvinen; Kerry S Courneya; Ronald C Plotnikoff; John C Spence; Peter M Venner; Scott North Journal: Support Care Cancer Date: 2008-06-06 Impact factor: 3.603